Onco Care
Early
Cancer
Detection
Spot cancer early when it is still very small and enable treatment personalization by catching tumor info from the blood and analyzing it
Onco Care
Early
Cancer
Detection
Spot cancer early when it is still very small and enable treatment personalization by catching tumor info from the blood and analyzing it
About
Onco Care
Our test needs only one tube of blood, could avoid surgery, and could find many cancers earlier than imaging, some biomarkers or blood DNA‑only tests. Earlier detection means simpler treatments, better quality of life, better survival and lower costs. Could detect multiple cancers at early stages, and reveal biological significant information such as survival, resistance, aggressiveness
Statistics
Benefits
The Problem
Therapy gap: treatment choice is often trial-and-error → wasted time and costs
For this disease, medical guides are simply far from enough. Traditional biomarkers can be misleading, for example, PSA for prostate cancer can be low even in advanced forms of metastatic and resistant prostate cancer, and current imaging and blood biomarker methods can delay detection until the disease is advanced, when it is too late, 90% of deaths occur due to metastasis
Early Detection Impact
Earlier detection means simpler treatments, better quality of life, better survival and lower costs
Cancer Detection Today
In Europe alone, cancer causes about 1.9 million deaths annually, and is growing. It is urgent to find better detection and personalized treatment methods
A New Diagnostic Approach
For these reasons, expert organisations like the European Society of Medical Oncology (ESMO) have been advocating for increased tumor biopsy sampling to facilitate personalized therapies and monitor responses in real time. Currently, a tissue biopsy is the norm, but this invasive procedure has risks of complications, does not capture all tumor complexity, and it is not practical for monitoring, mainly because of repeatability, morbidity, costs and time, leading to clinical complications
The alternative? Liquid biopsy consists of taking tumor-originated material from fluids such as blood. It overcomes the spatial and temporal limitations of tissue biopsies, and provides a dynamic snapshot of tumor evolution and resistance mechanisms. This is why liquid biopsy is increasingly seen as a crucial tool for non-invasive, rapid, real-time monitoring. It is evident that detecting cancer earlier improves outcomes (90-99% depending on the cancer type), and studies have shown that liquid biopsy monitoring can detect treatment resistance before it appears on imaging: this could save very many lives
Current Limitations
Traditional tissue biopsy (surgery) is currently used in the US and Europe. Transitioning to liquid biopsy has been a top priority in many countries for years, but hasn't been achieved yet for solid tumors
US players (Grail, Freenome, Guardant) look mostly at cell-free DNA, missing many early tumours. They only work in later stages when cancer is less treatable
Our Approach
We detect cancer earlier, more sensitively and more linked to biological significance (survival, resistance, aggressiveness)
From a blood test, Onco Care uses proprietary AI-driven multiomics and a sensitivity-enhanced protocol to detect multiple cancers at early stages, revealing biological significant information
Platform Features
Our
Vision
The standard-of-care for all solid cancers, delivering annual, non-invasive tumor check-ups that catch disease when it is still microscopic and algorithmically guiding every patient to the therapy with the best survival odds
Early Detection
Aim to be a leading early-cancer test across Europe and the US
Key Milestones
Our roadmap to transforming cancer care through early detection and personalized treatment
Global Impact
Focus on impact across Europe and the US, targeting broad early-detection access and outcomes
Innovation Focus
For all solid cancers, the standard-of-care providing annual non-invasive tumor check-ups, early detection at the microscopic stage, and algorithmic guidance toward therapies with the highest survival odds
Patient-Centered
Improve survival odds through early detection and therapy guidance
Detect cancer earlier than imaging or standard biomarkers and even predict prognosis, aggressiveness, resistance, recurrence
Make these decisions early, while there's still time to help your patient
Contact
Us
Join our waitlist for treatment personalization and tumor profiling
Current ubications
Send us a message
Get in touch
Email Us
laura@onco-care.io
We'll respond within 24 hours
Solutions for
Healthcare institutions
Guidelines for both doctors and patients
Clinical Labs
New exclusive test for your portfolio
Insurers
Exclusive offer for your clients